We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Knowledge and Competence Support Platform Improves POC Testing

By LabMedica International staff writers
Posted on 10 Feb 2009
A knowledge and competence support platform is designed to improve and test user competency in point-of-care (POC) testing through online courses and examination. More...


POC is a growing field and is increasingly governed by regulatory requirements including competence assessment and training on a regular basis. Training in many countries is emerging as a compulsory expectation in POC management.

Continuous quality assurance of POC means ongoing recertification of standards. The Cobas academy is suitable for providing courses and exams for recertification to large numbers of staff. Knowledgeable and competent end users can deliver better use and greater reliability of POC devices, fewer errors in each of the analytic stages, and more appropriate use of lab resources.

Cobas academy's primary function is to test user competency after the initial face-to-face training. Accessible on the hospital intranet, it offers the user an optional pre-test that generates a study plan to focus only on required areas. The platform offers greater flexibility in training delivery and the opportunity to involve a larger group of staff.

Roche Diagnostics (Rotkreuz, Switzerland) launched the new knowledge and competence support platform, which currently offers three courses cobas b 221, Accu-Chek Inform, and Accu-Chek Inform II. Cobas academy is available in countries that proffer cobas IT (information technology) 1000 solutions.

Roche is a developer of in vitro diagnostics (IVD), drugs for cancer, transplantation, and virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system (CNS).

Related Links:
Roche



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.